October 16-17, 2017  |  Orlando, Florida USA

An Official Satellite Event to the American Society of Human Genetics (ASHG) Annual Meeting

REQUEST A BROCHURE

The Personalized/Precision Medicine Blog

The official blog of the Annual Personalized and Precision Medicine Conference provides readers with information, insight and analysis regarding the field of personalized and precision medicine, genomics, genomic interpretation and the evolution of healthcare in the post-genomic era.

Novartis, Pfizer and Thermo Fisher to Lead Panel Discussion on Developing a Universal Test NGS-Based Companion Diagnostic Designed to Support Multiple Drug Development Programs

In 2015, Novartis, Pfizer and Thermo Fisher Scientific announced a long-term partnership, with the hopes of accelerating the development and registration of several new non-small cell lung cancer (NSCLC) drugs. Over the past year, this collaboration has worked on developing and commercializing a multi-marker, universal next-generation sequencing oncology test that will serve as a companion diagnostic for NSCLC across multiple drug platforms. 
 
Executives from Novartis, Thermo Fisher and Pfizer will be leading a panel discussion at the 8th Annual Personalized and Precision Medicine Conference, taking place October 12-13, 2016 in San Francisco, CA.  For more information on the conference, visit: http://personalizedmedicinepartnerships.com. 
 
The three executives that will lead this panel discussion are:
Mark Stevenson, MBA, Executive VP and President of Life Science Solutions, Thermo Fisher
Anne-Marie Martin, Ph.D., Senior VP, Global Head of Precision Medicine, Novartis
Hakan Sakul, Ph.D., VP and Head of Diagnostics, Pfizer
 
As there is a growing demand for targeted therapies to replace the “one-size-fits-all” paradigm, stakeholders in the health care industry are looking to satisfy the ultimate goal of providing more personalized therapies and timely access to the appropriate clinical trials. With the continued use of next-generation sequencing, which allows for multiple genes to be simultaneously tested from a single sample, personalized and precision medicine are on the forefront of revolutionizing the health care industry.
 
The NGS-based companion diagnostic test for NSCLC is being developed using Thermo Fisher’s Ion PGM Dx System and Oncomine assays. Hakan Sakul commented on the collaboration, “the Thermo Fisher Scientific NGS panel is aligned with a number of our clinical development programs, providing us with an opportunity to accelerate the development of each of these potential therapies for NSCLC patients with targetable genetic alterations.”
 
Mark Stevenson of Thermo Fisher also commented that, “the potential to generate a paradigm shift through this agreement – from one test for one drug, to one test for multiple NSCLC therapies, represents a significant step forward in realizing the promise of precision medicine.” For more information on the collaboration, visit: http://news.thermofisher.com/press-release/life-technologies/thermo-fisher-scientific-signs-development-agreement-next-generation.
 
Rate this blog entry:
Syapse Founder Jonathan Hirsch to Present a New Vi...

Related Posts

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at www.arrowheadpublishers.com.

Contact Us

For general information about the conference, please contact us at:
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 +866.945.0263
 +866.945.0263
 5780 Lincoln Drive, Suite 205, Edina, Minnesota 55436 USA